[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fhNX-SaDVGhfY-24_s-pf0O9Xviddr_xnRQXB3Z24DeU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":9,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":82,"rows":89},"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",[4],56,false,17,18,14712,20,[13,16,19,21,23,25,27,29],{"name":14,"count":15},"Myelodysplastic Syndromes",4,{"name":17,"count":18},"Wiskott-Aldrich Syndrome",3,{"name":20,"count":18},"Ganglioneuroblastoma",{"name":22,"count":18},"Childhood Acute Lymphoblastic Leukemia",{"name":24,"count":18},"Acute Myeloid Leukemia",{"name":26,"count":18},"Nijmegen Breakage Syndrome",{"name":28,"count":18},"Acute Lymphoblastic Leukemia",{"name":30,"count":18},"Biphenotypic Acute Leukemia",[32,37,42,47,52,57,62,67,72,77],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT04499573","Bispecific CD19\u002FCD22 CAR-T for Treatment of Children and Young Adults With r\u002Fr B-ALL","2022-03-13","CD19\u002FCD22 CAR-T",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06475820","Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis","2024-07-01","Baricitinib",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05515029","Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis","2024-08-15","GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05518383","B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021","2025-05-16","Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06756152","Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis","2026-07-10","Conditioning regimen: Treosulfan 42 g\u002Fm2\u002Fcourse or total body irradiation 12 Gray\u002Fcourse, Etoposide 60 mg\u002Fkg , Fludarabine 150",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06071897","Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma","2026-09-01","monoclonal antibodies GD2",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07256210","Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation","2026-10","Donor-derived Natural Killer Cell",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06199427","PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity","2026-11-21","Cyclophosphamide",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07375563","Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma","2026-12-15","Dinutuximab beta, temozolomide, irinotecan, autologous NK cell",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06198842","Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome","2027-01-31","Treosulfan",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,122,140,158,176,220,246,264,288,310,336,357,381,404,422,449,479,521,556,577,599,634,678,704,735,762,780,805,833,851,869,887,918,947,974,992,1010,1028,1053,1071,1089,1107,1125,1150,1168,1193,1234,1262,1296,1314,1332,1350,1368,1386,1404,1422,1440,1458,1482,1505,1523,1541,1559,1577,1595],{"intervention":51,"totalTrials":91,"cells":92},1,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":120},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[],{"trials":103,"activeCount":91,"soonestReadout":50},[104],{"nctId":48,"briefTitle":49,"status":105,"phases":106,"primaryCompletion":50,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":116},"RECRUITING",[87],"2027-05-16","2022-05-25",300,[111,112,113,114,115],"Non-hodgkin Lymphoma,B Cell","Burkitt Lymphoma","Primary Mediastinal Lymphoma","Primary CNS Lymphoma","Diffuse Large B-cell Lymphoma",[51,117,118,119],"Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine","Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine","Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU\u002F BCNU, Melphalan, Idarubicin",{"trials":121,"activeCount":95},[],{"intervention":117,"totalTrials":91,"cells":123},{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":132,"NA":138},{"trials":125,"activeCount":95},[],{"trials":127,"activeCount":95},[],{"trials":129,"activeCount":95},[],{"trials":131,"activeCount":95},[],{"trials":133,"activeCount":91,"soonestReadout":50},[134],{"nctId":48,"briefTitle":49,"status":105,"phases":135,"primaryCompletion":50,"completion":107,"start":108,"enrollment":109,"conditions":136,"interventions":137},[87],[111,112,113,114,115],[51,117,118,119],{"trials":139,"activeCount":95},[],{"intervention":118,"totalTrials":91,"cells":141},{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":156},{"trials":143,"activeCount":95},[],{"trials":145,"activeCount":95},[],{"trials":147,"activeCount":95},[],{"trials":149,"activeCount":95},[],{"trials":151,"activeCount":91,"soonestReadout":50},[152],{"nctId":48,"briefTitle":49,"status":105,"phases":153,"primaryCompletion":50,"completion":107,"start":108,"enrollment":109,"conditions":154,"interventions":155},[87],[111,112,113,114,115],[51,117,118,119],{"trials":157,"activeCount":95},[],{"intervention":119,"totalTrials":91,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":174},{"trials":161,"activeCount":95},[],{"trials":163,"activeCount":95},[],{"trials":165,"activeCount":95},[],{"trials":167,"activeCount":95},[],{"trials":169,"activeCount":91,"soonestReadout":50},[170],{"nctId":48,"briefTitle":49,"status":105,"phases":171,"primaryCompletion":50,"completion":107,"start":108,"enrollment":109,"conditions":172,"interventions":173},[87],[111,112,113,114,115],[51,117,118,119],{"trials":175,"activeCount":95},[],{"intervention":177,"totalTrials":178,"cells":179},"Sirolimus",2,{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":216,"NA":218},{"trials":181,"activeCount":95},[],{"trials":183,"activeCount":95},[],{"trials":185,"activeCount":95},[],{"trials":187,"activeCount":178,"soonestReadout":192},[188,205],{"nctId":189,"briefTitle":190,"status":105,"phases":191,"primaryCompletion":192,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":201},"NCT07366801","Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies",[85,86],"2027-06-01","2028-02-03","2025-09-03",64,[197,198,199,200],"Acute Myeloid Leukemia, Relapsed","Acute Lymphoblastic Leukemia, High Risk","Acute Myeloid Leukemia, High Risk","Acute Lymphoblastic Leukemia, Relapse",[202,177,203,204],"Cyclosporine A","Ruxolitinib","Abatacept",{"nctId":206,"briefTitle":207,"status":105,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT05549167","Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)",[86],"2029-09-30","2029-12-30","2022-05-30",117,[214],"Juvenile Nasopharyngeal Angiofibroma",[177],{"trials":217,"activeCount":95},[],{"trials":219,"activeCount":95},[],{"intervention":203,"totalTrials":178,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":236,"PHASE4":242,"NA":244},{"trials":223,"activeCount":95},[],{"trials":225,"activeCount":95},[],{"trials":227,"activeCount":91,"soonestReadout":70},[228],{"nctId":68,"briefTitle":69,"status":105,"phases":229,"primaryCompletion":70,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},[85],"2027-12-31","2023-11-21",100,[234],"Inborn Errors of Immunity",[71,203],{"trials":237,"activeCount":91,"soonestReadout":192},[238],{"nctId":189,"briefTitle":190,"status":105,"phases":239,"primaryCompletion":192,"completion":193,"start":194,"enrollment":195,"conditions":240,"interventions":241},[85,86],[197,198,199,200],[202,177,203,204],{"trials":243,"activeCount":95},[],{"trials":245,"activeCount":95},[],{"intervention":202,"totalTrials":91,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":260,"NA":262},{"trials":249,"activeCount":95},[],{"trials":251,"activeCount":95},[],{"trials":253,"activeCount":95},[],{"trials":255,"activeCount":91,"soonestReadout":192},[256],{"nctId":189,"briefTitle":190,"status":105,"phases":257,"primaryCompletion":192,"completion":193,"start":194,"enrollment":195,"conditions":258,"interventions":259},[85,86],[197,198,199,200],[202,177,203,204],{"trials":261,"activeCount":95},[],{"trials":263,"activeCount":95},[],{"intervention":46,"totalTrials":91,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":284,"NA":286},{"trials":267,"activeCount":95},[],{"trials":269,"activeCount":95},[],{"trials":271,"activeCount":95},[],{"trials":273,"activeCount":91,"soonestReadout":45},[274],{"nctId":43,"briefTitle":44,"status":275,"phases":276,"primaryCompletion":45,"completion":277,"start":278,"enrollment":6,"conditions":279,"interventions":283},"ACTIVE_NOT_RECRUITING",[86],"2026-10-16","2022-08-23",[28,280,30,281,14,282],"Myeloblastic Leukemia","Malignant Lymphoma","Juvenile Myelomonocytic Leukemia",[46],{"trials":285,"activeCount":95},[],{"trials":287,"activeCount":95},[],{"intervention":61,"totalTrials":91,"cells":289},{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":296,"PHASE4":306,"NA":308},{"trials":291,"activeCount":95},[],{"trials":293,"activeCount":95},[],{"trials":295,"activeCount":95},[],{"trials":297,"activeCount":91,"soonestReadout":60},[298],{"nctId":58,"briefTitle":59,"status":105,"phases":299,"primaryCompletion":60,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},[86],"2029-09-01","2023-09-01",15,[304,20],"Neuroblastoma",[61],{"trials":307,"activeCount":95},[],{"trials":309,"activeCount":95},[],{"intervention":311,"totalTrials":91,"cells":312},"4 chemotherapy blocks: Course 1 AIE (cytarabine\u002Fidarubicin\u002Fetoposide), Course 2 AI (cytarabine\u002Fidarubicin), Course 3 HAD (high-dose cytarabine (1g)\u002Fdaunorubicin), Course 4 HA (high-dose cytarabine).",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":332,"NA":334},{"trials":314,"activeCount":95},[],{"trials":316,"activeCount":95},[],{"trials":318,"activeCount":95},[],{"trials":320,"activeCount":91,"soonestReadout":325},[321],{"nctId":322,"briefTitle":323,"status":105,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":232,"conditions":328,"interventions":331},"NCT07232134","The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia",[86],"2030-07-24","2032-12-30","2025-07-24",[329,330],"AML (Acute Myelogenous Leukemia)","Down Syndrome (DS)",[311],{"trials":333,"activeCount":95},[],{"trials":335,"activeCount":95},[],{"intervention":41,"totalTrials":91,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":353,"NA":355},{"trials":339,"activeCount":95},[],{"trials":341,"activeCount":95},[],{"trials":343,"activeCount":95},[],{"trials":345,"activeCount":91,"soonestReadout":40},[346],{"nctId":38,"briefTitle":39,"status":275,"phases":347,"primaryCompletion":40,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},[85,86],"2027-04-01","2023-12-01",150,[28,24,30,281,14],[41],{"trials":354,"activeCount":95},[],{"trials":356,"activeCount":95},[],{"intervention":56,"totalTrials":91,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":377,"NA":379},{"trials":360,"activeCount":95},[],{"trials":362,"activeCount":95},[],{"trials":364,"activeCount":95},[],{"trials":366,"activeCount":91,"soonestReadout":55},[367],{"nctId":53,"briefTitle":54,"status":105,"phases":368,"primaryCompletion":55,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":376},[85,86],"2026-10-10","2024-07-10",50,[30,28,280,373,374,375],"Bilinear Leukemia","Malignant Lymphoma, Non-Hodgkin","Myelodysplastic Syndrome",[56],{"trials":378,"activeCount":95},[],{"trials":380,"activeCount":95},[],{"intervention":76,"totalTrials":91,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":400,"NA":402},{"trials":384,"activeCount":95},[],{"trials":386,"activeCount":95},[],{"trials":388,"activeCount":95},[],{"trials":390,"activeCount":91,"soonestReadout":75},[391],{"nctId":73,"briefTitle":74,"status":105,"phases":392,"primaryCompletion":75,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":398},[86],"2028-11-19","2025-11-19",5,[397,20],"Neuroblastoma (NB)",[76,399],"irinotecan, temozolomide, dinutuximab beta, NK-cell product",{"trials":401,"activeCount":95},[],{"trials":403,"activeCount":95},[],{"intervention":399,"totalTrials":91,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":418,"NA":420},{"trials":407,"activeCount":95},[],{"trials":409,"activeCount":95},[],{"trials":411,"activeCount":95},[],{"trials":413,"activeCount":91,"soonestReadout":75},[414],{"nctId":73,"briefTitle":74,"status":105,"phases":415,"primaryCompletion":75,"completion":393,"start":394,"enrollment":395,"conditions":416,"interventions":417},[86],[397,20],[76,399],{"trials":419,"activeCount":95},[],{"trials":421,"activeCount":95},[],{"intervention":423,"totalTrials":91,"cells":424},"the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":445,"NA":447},{"trials":426,"activeCount":95},[],{"trials":428,"activeCount":95},[],{"trials":430,"activeCount":95},[],{"trials":432,"activeCount":91,"soonestReadout":437},[433],{"nctId":434,"briefTitle":435,"status":105,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":444},"NCT05029531","Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)",[86],"2029-07-01","2030-07-01","2021-09-23",80,[442,443],"Acute Lymphoblastic Leukemia, Pediatric","ALL, Infants",[423],{"trials":446,"activeCount":95},[],{"trials":448,"activeCount":95},[],{"intervention":204,"totalTrials":178,"cells":450},{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":463,"NA":465},{"trials":452,"activeCount":95},[],{"trials":454,"activeCount":95},[],{"trials":456,"activeCount":95},[],{"trials":458,"activeCount":91,"soonestReadout":192},[459],{"nctId":189,"briefTitle":190,"status":105,"phases":460,"primaryCompletion":192,"completion":193,"start":194,"enrollment":195,"conditions":461,"interventions":462},[85,86],[197,198,199,200],[202,177,203,204],{"trials":464,"activeCount":95},[],{"trials":466,"activeCount":95},[467],{"nctId":468,"briefTitle":469,"status":470,"phases":471,"primaryCompletion":472,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":477},"NCT04572620","Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.","UNKNOWN",[],"2021-09","2020-09-07",30,[476],"Interstitial Lymphocytic Lung Disease",[478,204],"Rituximab",{"intervention":81,"totalTrials":18,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":482,"activeCount":95},[],{"trials":484,"activeCount":95},[],{"trials":486,"activeCount":178,"soonestReadout":80},[487,496,509],{"nctId":488,"briefTitle":489,"status":470,"phases":490,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":495},"NCT04400045","Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome",[85],"2023-05","2020-05-22",10,[26],[81],{"nctId":497,"briefTitle":498,"status":499,"phases":500,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":508},"NCT07316595","Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome","NOT_YET_RECRUITING",[85],"2028-12-31","2030-12-31","2025-12-30",24,[506,26,507],"HSCT","Treosulfan Based Conditioning",[81],{"nctId":78,"briefTitle":79,"status":105,"phases":510,"primaryCompletion":80,"completion":511,"start":512,"enrollment":493,"conditions":513,"interventions":514},[85],"2029-01-31","2023-11-22",[26],[81],{"trials":516,"activeCount":95},[],{"trials":518,"activeCount":95},[],{"trials":520,"activeCount":95},[],{"intervention":71,"totalTrials":178,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":550,"PHASE4":552,"NA":554},{"trials":524,"activeCount":95},[],{"trials":526,"activeCount":95},[],{"trials":528,"activeCount":91,"soonestReadout":70},[529,533],{"nctId":68,"briefTitle":69,"status":105,"phases":530,"primaryCompletion":70,"completion":230,"start":231,"enrollment":232,"conditions":531,"interventions":532},[85],[234],[71,203],{"nctId":534,"briefTitle":535,"status":470,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":9,"conditions":540,"interventions":543},"NCT03467256","CD19 T-CAR for Treatment of Children and Young Adults With r\u002Fr B-ALL",[84,85],"2020-10-15","2025-10-15","2018-05-14",[541,542],"B-cell Acute Lymphoblastic Leukemia","Acute Lymphocytic Leukemia, Pediatric",[544,545,71,546,547,548,549],"Chimeric Antigen Receptor T-Cell Therapy","Fludarabine","Tocilizumab","Cytarabine","Etoposide","Dexamethasone",{"trials":551,"activeCount":95},[],{"trials":553,"activeCount":95},[],{"trials":555,"activeCount":95},[],{"intervention":36,"totalTrials":91,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":559,"activeCount":95},[],{"trials":561,"activeCount":95},[],{"trials":563,"activeCount":91,"soonestReadout":35},[564],{"nctId":33,"briefTitle":34,"status":275,"phases":565,"primaryCompletion":35,"completion":566,"start":567,"enrollment":371,"conditions":568,"interventions":570},[84,85],"2027-03-13","2020-07-27",[569],"B-ALL",[36],{"trials":572,"activeCount":95},[],{"trials":574,"activeCount":95},[],{"trials":576,"activeCount":95},[],{"intervention":66,"totalTrials":91,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":580,"activeCount":95},[],{"trials":582,"activeCount":95},[],{"trials":584,"activeCount":91,"soonestReadout":65},[585],{"nctId":63,"briefTitle":64,"status":105,"phases":586,"primaryCompletion":65,"completion":587,"start":588,"enrollment":302,"conditions":589,"interventions":592},[85],"2027-10","2025-05-09",[24,590,591],"Acute Lymphoblastic T-cell Leukemia","Mixed Phenotype Acute Leukemia",[66],{"trials":594,"activeCount":95},[],{"trials":596,"activeCount":95},[],{"trials":598,"activeCount":95},[],{"intervention":600,"totalTrials":178,"cells":601},"Eltrombopag",{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":618,"PHASE4":630,"NA":632},{"trials":603,"activeCount":95},[],{"trials":605,"activeCount":95},[],{"trials":607,"activeCount":95},[608],{"nctId":609,"briefTitle":610,"status":470,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":474,"conditions":615,"interventions":616},"NCT04371939","Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome",[85],"2022-12","2023-07-30","2019-11-05",[17],[617,600],"Romiplostim",{"trials":619,"activeCount":95},[620],{"nctId":621,"briefTitle":622,"status":470,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":232,"conditions":626,"interventions":628},"NCT03413306","Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA",[86],"2022-10-20","2016-12-10",[627],"Acquired Aplastic Anemia",[600,629],"IST",{"trials":631,"activeCount":95},[],{"trials":633,"activeCount":95},[],{"intervention":635,"totalTrials":178,"cells":636},"CD45RA-depleted peripheral blood mononuclear cells",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":659,"PHASE4":674,"NA":676},{"trials":638,"activeCount":95},[],{"trials":640,"activeCount":95},[],{"trials":642,"activeCount":95},[643],{"nctId":644,"briefTitle":645,"status":646,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":474,"conditions":651,"interventions":658},"NCT02337595","Memory T-cell Infusion to Improve Immunity After TCR-alpha\u002FBeta Depleted Hematopoietic Stem Cell Transplantation","COMPLETED",[84,85],"2015-03","2016-01","2014-08",[652,653,654,655,656,657],"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","Leukemia, Myeloid, Acute","Immune Deficiency Disease","Bone Marrow Failure Syndromes","Opportunistic Infections","Graft vs Host Disease",[635],{"trials":660,"activeCount":95},[661],{"nctId":662,"briefTitle":663,"status":646,"phases":664,"primaryCompletion":665,"completion":666,"start":667,"enrollment":350,"conditions":668,"interventions":673},"NCT02942173","CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab\u002FCD19-depleted Allo-HSCT",[85,86],"2019-08-21","2020-08-21","2016-10",[669,670,14,671,656,672],"Leukemia","Lymphoma","GvHD","Graft-versus-Host Disease",[635],{"trials":675,"activeCount":95},[],{"trials":677,"activeCount":95},[],{"intervention":679,"totalTrials":91,"cells":680},"Preparative regimen",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":700,"NA":702},{"trials":682,"activeCount":95},[],{"trials":684,"activeCount":95},[],{"trials":686,"activeCount":95},[],{"trials":688,"activeCount":95},[689],{"nctId":690,"briefTitle":691,"status":470,"phases":692,"primaryCompletion":693,"completion":612,"start":694,"enrollment":695,"conditions":696,"interventions":699},"NCT04000698","Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias",[86],"2022-07","2019-10-15",25,[697,698],"Refractory Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia",[679],{"trials":701,"activeCount":95},[],{"trials":703,"activeCount":95},[],{"intervention":705,"totalTrials":91,"cells":706},"Sugammadex",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":731,"NA":733},{"trials":708,"activeCount":95},[],{"trials":710,"activeCount":95},[],{"trials":712,"activeCount":95},[],{"trials":714,"activeCount":95},[715],{"nctId":716,"briefTitle":717,"status":470,"phases":718,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":730},"NCT03728543","the Efficacy and Safety of Sugammadex in Children 0-2 Years Old",[85,86],"2019-11-15","2019-11-20","2018-11-15",62,[724,725,726,727,728,729],"Anesthesia","Pediatric Cancer","Pediatric Tumor","Pediatric Hepatoblastoma","Beta-Thalassemia","Hepatic Metastases",[705],{"trials":732,"activeCount":95},[],{"trials":734,"activeCount":95},[],{"intervention":736,"totalTrials":91,"cells":737},"Riboflavin+UV RBC",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":758,"NA":760},{"trials":739,"activeCount":95},[],{"trials":741,"activeCount":95},[],{"trials":743,"activeCount":95},[],{"trials":745,"activeCount":95},[746],{"nctId":747,"briefTitle":748,"status":646,"phases":749,"primaryCompletion":750,"completion":751,"start":752,"enrollment":371,"conditions":753,"interventions":756},"NCT03426553","Clinical Use of Pathogen Reduced Red Blood Cell Suspension",[86],"2018-09-17","2018-12-17","2018-01-15",[754,755],"Oncologic Disorders","Hematologic Diseases",[736,757],"irradiated RBC",{"trials":759,"activeCount":95},[],{"trials":761,"activeCount":95},[],{"intervention":757,"totalTrials":91,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":776,"NA":778},{"trials":765,"activeCount":95},[],{"trials":767,"activeCount":95},[],{"trials":769,"activeCount":95},[],{"trials":771,"activeCount":95},[772],{"nctId":747,"briefTitle":748,"status":646,"phases":773,"primaryCompletion":750,"completion":751,"start":752,"enrollment":371,"conditions":774,"interventions":775},[86],[754,755],[736,757],{"trials":777,"activeCount":95},[],{"trials":779,"activeCount":95},[],{"intervention":781,"totalTrials":91,"cells":782},"Crizotinib",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":801,"NA":803},{"trials":784,"activeCount":95},[],{"trials":786,"activeCount":95},[],{"trials":788,"activeCount":95},[],{"trials":790,"activeCount":95},[791],{"nctId":792,"briefTitle":793,"status":470,"phases":794,"primaryCompletion":795,"completion":796,"start":797,"enrollment":695,"conditions":798,"interventions":800},"NCT03874273","Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors",[85,86],"2021-02-01","2021-03-01","2019-02-01",[799],"Inflammatory Myofibroblastic Tumor",[781],{"trials":802,"activeCount":95},[],{"trials":804,"activeCount":95},[],{"intervention":806,"totalTrials":91,"cells":807},"Ondansetron",{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":814,"PHASE4":829,"NA":831},{"trials":809,"activeCount":95},[],{"trials":811,"activeCount":95},[],{"trials":813,"activeCount":95},[],{"trials":815,"activeCount":95},[816],{"nctId":817,"briefTitle":818,"status":470,"phases":819,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":826},"NCT05346731","Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents",[86],"2024-03","2024-08","2022-04-01",210,[825],"Chemotherapy-induced Nausea and Vomiting",[806,549,827,828],"Aprepitant","Olanzapine",{"trials":830,"activeCount":95},[],{"trials":832,"activeCount":95},[],{"intervention":827,"totalTrials":91,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":847,"NA":849},{"trials":836,"activeCount":95},[],{"trials":838,"activeCount":95},[],{"trials":840,"activeCount":95},[],{"trials":842,"activeCount":95},[843],{"nctId":817,"briefTitle":818,"status":470,"phases":844,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":845,"interventions":846},[86],[825],[806,549,827,828],{"trials":848,"activeCount":95},[],{"trials":850,"activeCount":95},[],{"intervention":828,"totalTrials":91,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":865,"NA":867},{"trials":854,"activeCount":95},[],{"trials":856,"activeCount":95},[],{"trials":858,"activeCount":95},[],{"trials":860,"activeCount":95},[861],{"nctId":817,"briefTitle":818,"status":470,"phases":862,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":863,"interventions":864},[86],[825],[806,549,827,828],{"trials":866,"activeCount":95},[],{"trials":868,"activeCount":95},[],{"intervention":629,"totalTrials":91,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":883,"NA":885},{"trials":872,"activeCount":95},[],{"trials":874,"activeCount":95},[],{"trials":876,"activeCount":95},[],{"trials":878,"activeCount":95},[879],{"nctId":621,"briefTitle":622,"status":470,"phases":880,"primaryCompletion":624,"completion":624,"start":625,"enrollment":232,"conditions":881,"interventions":882},[86],[627],[600,629],{"trials":884,"activeCount":95},[],{"trials":886,"activeCount":95},[],{"intervention":547,"totalTrials":178,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":890,"activeCount":95},[],{"trials":892,"activeCount":95},[],{"trials":894,"activeCount":95},[895,908],{"nctId":896,"briefTitle":897,"status":470,"phases":898,"primaryCompletion":899,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":905},"NCT03585686","A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation",[85],"2023-04","2023-12","2018-06-26",12,[904],"Langerhans Cell Histiocytosis",[906,547,907],"Vemurafenib","2-chlorodeoxyadenosine",{"nctId":534,"briefTitle":535,"status":470,"phases":909,"primaryCompletion":537,"completion":538,"start":539,"enrollment":9,"conditions":910,"interventions":911},[84,85],[541,542],[544,545,71,546,547,548,549],{"trials":913,"activeCount":95},[],{"trials":915,"activeCount":95},[],{"trials":917,"activeCount":95},[],{"intervention":919,"totalTrials":91,"cells":920},"boost anti-viral immunity after T-cell depleted HSCT",{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":925,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":922,"activeCount":95},[],{"trials":924,"activeCount":95},[],{"trials":926,"activeCount":95},[927],{"nctId":928,"briefTitle":929,"status":470,"phases":930,"primaryCompletion":931,"completion":932,"start":933,"enrollment":11,"conditions":934,"interventions":940},"NCT05066958","Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT",[84,85],"2022-09-01","2022-12-01","2021-09-16",[24,935,936,937,938,939,14],"High Risk Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia, in Relapse","High Risk Acute Lymphoblastic Leukemia","Acute Biphenotypic Leukemia in Relapse","Non-hodgkin Lymphoma",[919],{"trials":942,"activeCount":95},[],{"trials":944,"activeCount":95},[],{"trials":946,"activeCount":95},[],{"intervention":948,"totalTrials":91,"cells":949},"G-CSF for Conditioning before HSCT.",{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":951,"activeCount":95},[],{"trials":953,"activeCount":95},[],{"trials":955,"activeCount":95},[956],{"nctId":957,"briefTitle":958,"status":470,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":474,"conditions":963,"interventions":966},"NCT03019809","A Trial of Plerixafor\u002FG-CSF as Additional Agents for Conditioning Before TCR Alpha\u002FBeta Depleted HSCT in WAS Patients",[85],"2018-12","2019-07","2016-06",[17,964,965],"Hematopoietic Stem Cell Transplantation","Graft Failure",[948,967],"Plerixafor for Conditioning before HSCT.",{"trials":969,"activeCount":95},[],{"trials":971,"activeCount":95},[],{"trials":973,"activeCount":95},[],{"intervention":967,"totalTrials":91,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":977,"activeCount":95},[],{"trials":979,"activeCount":95},[],{"trials":981,"activeCount":95},[982],{"nctId":957,"briefTitle":958,"status":470,"phases":983,"primaryCompletion":960,"completion":961,"start":962,"enrollment":474,"conditions":984,"interventions":985},[85],[17,964,965],[948,967],{"trials":987,"activeCount":95},[],{"trials":989,"activeCount":95},[],{"trials":991,"activeCount":95},[],{"intervention":906,"totalTrials":91,"cells":993},{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":995,"activeCount":95},[],{"trials":997,"activeCount":95},[],{"trials":999,"activeCount":95},[1000],{"nctId":896,"briefTitle":897,"status":470,"phases":1001,"primaryCompletion":899,"completion":900,"start":901,"enrollment":902,"conditions":1002,"interventions":1003},[85],[904],[906,547,907],{"trials":1005,"activeCount":95},[],{"trials":1007,"activeCount":95},[],{"trials":1009,"activeCount":95},[],{"intervention":907,"totalTrials":91,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1013,"activeCount":95},[],{"trials":1015,"activeCount":95},[],{"trials":1017,"activeCount":95},[1018],{"nctId":896,"briefTitle":897,"status":470,"phases":1019,"primaryCompletion":899,"completion":900,"start":901,"enrollment":902,"conditions":1020,"interventions":1021},[85],[904],[906,547,907],{"trials":1023,"activeCount":95},[],{"trials":1025,"activeCount":95},[],{"trials":1027,"activeCount":95},[],{"intervention":1029,"totalTrials":91,"cells":1030},"Brentuximab Vedotin",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":1032,"activeCount":95},[],{"trials":1034,"activeCount":95},[],{"trials":1036,"activeCount":95},[1037],{"nctId":1038,"briefTitle":1039,"status":470,"phases":1040,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":440,"conditions":1044,"interventions":1046},"NCT03474133","Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)",[85],"2023-10-01","2023-12-02","2019-05-14",[1045],"Hodgkin's Lymphoma",[1029],{"trials":1048,"activeCount":95},[],{"trials":1050,"activeCount":95},[],{"trials":1052,"activeCount":95},[],{"intervention":544,"totalTrials":91,"cells":1054},{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1065,"PHASE4":1067,"NA":1069},{"trials":1056,"activeCount":95},[],{"trials":1058,"activeCount":95},[],{"trials":1060,"activeCount":95},[1061],{"nctId":534,"briefTitle":535,"status":470,"phases":1062,"primaryCompletion":537,"completion":538,"start":539,"enrollment":9,"conditions":1063,"interventions":1064},[84,85],[541,542],[544,545,71,546,547,548,549],{"trials":1066,"activeCount":95},[],{"trials":1068,"activeCount":95},[],{"trials":1070,"activeCount":95},[],{"intervention":545,"totalTrials":91,"cells":1072},{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1074,"activeCount":95},[],{"trials":1076,"activeCount":95},[],{"trials":1078,"activeCount":95},[1079],{"nctId":534,"briefTitle":535,"status":470,"phases":1080,"primaryCompletion":537,"completion":538,"start":539,"enrollment":9,"conditions":1081,"interventions":1082},[84,85],[541,542],[544,545,71,546,547,548,549],{"trials":1084,"activeCount":95},[],{"trials":1086,"activeCount":95},[],{"trials":1088,"activeCount":95},[],{"intervention":546,"totalTrials":91,"cells":1090},{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1101,"PHASE4":1103,"NA":1105},{"trials":1092,"activeCount":95},[],{"trials":1094,"activeCount":95},[],{"trials":1096,"activeCount":95},[1097],{"nctId":534,"briefTitle":535,"status":470,"phases":1098,"primaryCompletion":537,"completion":538,"start":539,"enrollment":9,"conditions":1099,"interventions":1100},[84,85],[541,542],[544,545,71,546,547,548,549],{"trials":1102,"activeCount":95},[],{"trials":1104,"activeCount":95},[],{"trials":1106,"activeCount":95},[],{"intervention":548,"totalTrials":91,"cells":1108},{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1110,"activeCount":95},[],{"trials":1112,"activeCount":95},[],{"trials":1114,"activeCount":95},[1115],{"nctId":534,"briefTitle":535,"status":470,"phases":1116,"primaryCompletion":537,"completion":538,"start":539,"enrollment":9,"conditions":1117,"interventions":1118},[84,85],[541,542],[544,545,71,546,547,548,549],{"trials":1120,"activeCount":95},[],{"trials":1122,"activeCount":95},[],{"trials":1124,"activeCount":95},[],{"intervention":1126,"totalTrials":91,"cells":1127},"Plerixafor",{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1144,"PHASE4":1146,"NA":1148},{"trials":1129,"activeCount":95},[],{"trials":1131,"activeCount":95},[],{"trials":1133,"activeCount":95},[1134],{"nctId":1135,"briefTitle":1136,"status":470,"phases":1137,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":8,"conditions":1140,"interventions":1142},"NCT03547830","Plerixafor\u002FG-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients",[85],"2023-01-01","2019-04-13",[1141],"Chronic Granulomatous Disease",[1126,1143],"Gcsf",{"trials":1145,"activeCount":95},[],{"trials":1147,"activeCount":95},[],{"trials":1149,"activeCount":95},[],{"intervention":1143,"totalTrials":91,"cells":1151},{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1153,"activeCount":95},[],{"trials":1155,"activeCount":95},[],{"trials":1157,"activeCount":95},[1158],{"nctId":1135,"briefTitle":1136,"status":470,"phases":1159,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":8,"conditions":1160,"interventions":1161},[85],[1141],[1126,1143],{"trials":1163,"activeCount":95},[],{"trials":1165,"activeCount":95},[],{"trials":1167,"activeCount":95},[],{"intervention":1169,"totalTrials":91,"cells":1170},"Kineret",{"EARLY_PHASE1":1171,"PHASE1":1183,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1172,"activeCount":95},[1173],{"nctId":1174,"briefTitle":1175,"status":646,"phases":1176,"primaryCompletion":1177,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1182},"NCT04136028","IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease",[83],"2019-01-16","2020-01","2015-09-25",13,[1141],[1169],{"trials":1184,"activeCount":95},[],{"trials":1186,"activeCount":95},[],{"trials":1188,"activeCount":95},[],{"trials":1190,"activeCount":95},[],{"trials":1192,"activeCount":95},[],{"intervention":549,"totalTrials":18,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1205,"PHASE4":1211,"NA":1213},{"trials":1196,"activeCount":95},[],{"trials":1198,"activeCount":95},[],{"trials":1200,"activeCount":95},[1201],{"nctId":534,"briefTitle":535,"status":470,"phases":1202,"primaryCompletion":537,"completion":538,"start":539,"enrollment":9,"conditions":1203,"interventions":1204},[84,85],[541,542],[544,545,71,546,547,548,549],{"trials":1206,"activeCount":95},[1207],{"nctId":817,"briefTitle":818,"status":470,"phases":1208,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":1209,"interventions":1210},[86],[825],[806,549,827,828],{"trials":1212,"activeCount":95},[],{"trials":1214,"activeCount":95},[1215],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1218,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1223,"interventions":1224},"NCT03390387","Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)",[88],"2020-11","2025-11","2015-11",4000,[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],"Dexamethasone continuous","Dexamethasone intermittent","Methylprednisolone","Daunorubicin","Idarubicin","Bortezomib","Second phase of induction","Standard induction therapy","Standard consolidation therapy",{"intervention":617,"totalTrials":178,"cells":1235},{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1237,"activeCount":95},[],{"trials":1239,"activeCount":95},[],{"trials":1241,"activeCount":95},[1242],{"nctId":609,"briefTitle":610,"status":470,"phases":1243,"primaryCompletion":612,"completion":613,"start":614,"enrollment":474,"conditions":1244,"interventions":1245},[85],[17],[617,600],{"trials":1247,"activeCount":95},[],{"trials":1249,"activeCount":95},[],{"trials":1251,"activeCount":95},[1252],{"nctId":1253,"briefTitle":1254,"status":646,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1261},"NCT04350164","Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.",[],"2019-12-27","2020-06","2012-04-01",67,[17],[617],{"intervention":1228,"totalTrials":178,"cells":1263},{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1265,"activeCount":95},[],{"trials":1267,"activeCount":95},[],{"trials":1269,"activeCount":95},[],{"trials":1271,"activeCount":95},[],{"trials":1273,"activeCount":95},[],{"trials":1275,"activeCount":95},[1276,1280],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1277,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1278,"interventions":1279},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"nctId":1281,"briefTitle":1282,"status":470,"phases":1283,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1289},"NCT01953770","Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008",[88],"2015-01","2020-07","2008-02",3000,[22],[1290,1291,1292,1293,1294,1295,1228],"PEG-L-asparaginase ind","PEG-L-asparaginase cons","E.coli L-asparaginase","High-dose Methotrexate","Low-dose Methotrexate","Triple intrathecal therapy",{"intervention":1225,"totalTrials":91,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1299,"activeCount":95},[],{"trials":1301,"activeCount":95},[],{"trials":1303,"activeCount":95},[],{"trials":1305,"activeCount":95},[],{"trials":1307,"activeCount":95},[],{"trials":1309,"activeCount":95},[1310],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1311,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1312,"interventions":1313},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"intervention":1226,"totalTrials":91,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1317,"activeCount":95},[],{"trials":1319,"activeCount":95},[],{"trials":1321,"activeCount":95},[],{"trials":1323,"activeCount":95},[],{"trials":1325,"activeCount":95},[],{"trials":1327,"activeCount":95},[1328],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1329,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1330,"interventions":1331},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"intervention":1227,"totalTrials":91,"cells":1333},{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1335,"activeCount":95},[],{"trials":1337,"activeCount":95},[],{"trials":1339,"activeCount":95},[],{"trials":1341,"activeCount":95},[],{"trials":1343,"activeCount":95},[],{"trials":1345,"activeCount":95},[1346],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1347,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1348,"interventions":1349},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"intervention":1229,"totalTrials":91,"cells":1351},{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1353,"activeCount":95},[],{"trials":1355,"activeCount":95},[],{"trials":1357,"activeCount":95},[],{"trials":1359,"activeCount":95},[],{"trials":1361,"activeCount":95},[],{"trials":1363,"activeCount":95},[1364],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1365,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1366,"interventions":1367},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"intervention":1230,"totalTrials":91,"cells":1369},{"EARLY_PHASE1":1370,"PHASE1":1372,"PHASE2":1374,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1371,"activeCount":95},[],{"trials":1373,"activeCount":95},[],{"trials":1375,"activeCount":95},[],{"trials":1377,"activeCount":95},[],{"trials":1379,"activeCount":95},[],{"trials":1381,"activeCount":95},[1382],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1383,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1384,"interventions":1385},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"intervention":1231,"totalTrials":91,"cells":1387},{"EARLY_PHASE1":1388,"PHASE1":1390,"PHASE2":1392,"PHASE3":1394,"PHASE4":1396,"NA":1398},{"trials":1389,"activeCount":95},[],{"trials":1391,"activeCount":95},[],{"trials":1393,"activeCount":95},[],{"trials":1395,"activeCount":95},[],{"trials":1397,"activeCount":95},[],{"trials":1399,"activeCount":95},[1400],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1401,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1402,"interventions":1403},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"intervention":1232,"totalTrials":91,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1407,"activeCount":95},[],{"trials":1409,"activeCount":95},[],{"trials":1411,"activeCount":95},[],{"trials":1413,"activeCount":95},[],{"trials":1415,"activeCount":95},[],{"trials":1417,"activeCount":95},[1418],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1419,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1420,"interventions":1421},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"intervention":1233,"totalTrials":91,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1425,"activeCount":95},[],{"trials":1427,"activeCount":95},[],{"trials":1429,"activeCount":95},[],{"trials":1431,"activeCount":95},[],{"trials":1433,"activeCount":95},[],{"trials":1435,"activeCount":95},[1436],{"nctId":1216,"briefTitle":1217,"status":470,"phases":1437,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1438,"interventions":1439},[88],[22],[1225,1226,549,1227,1228,1229,1230,1231,1232,1233],{"intervention":478,"totalTrials":91,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1450,"NA":1452},{"trials":1443,"activeCount":95},[],{"trials":1445,"activeCount":95},[],{"trials":1447,"activeCount":95},[],{"trials":1449,"activeCount":95},[],{"trials":1451,"activeCount":95},[],{"trials":1453,"activeCount":95},[1454],{"nctId":468,"briefTitle":469,"status":470,"phases":1455,"primaryCompletion":472,"completion":472,"start":473,"enrollment":474,"conditions":1456,"interventions":1457},[],[476],[478,204],{"intervention":1459,"totalTrials":91,"cells":1460},"Blinatumomab",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1462,"activeCount":95},[],{"trials":1464,"activeCount":95},[],{"trials":1466,"activeCount":95},[],{"trials":1468,"activeCount":95},[],{"trials":1470,"activeCount":95},[],{"trials":1472,"activeCount":95},[1473],{"nctId":1474,"briefTitle":1475,"status":470,"phases":1476,"primaryCompletion":612,"completion":1477,"start":1478,"enrollment":1479,"conditions":1480,"interventions":1481},"NCT04723342","Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot",[88],"2025-12","2020-02-01",180,[22],[1459],{"intervention":1483,"totalTrials":91,"cells":1484},"Cutaquig",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1493,"NA":1495},{"trials":1486,"activeCount":95},[],{"trials":1488,"activeCount":95},[],{"trials":1490,"activeCount":95},[],{"trials":1492,"activeCount":95},[],{"trials":1494,"activeCount":95},[],{"trials":1496,"activeCount":95},[1497],{"nctId":1498,"briefTitle":1499,"status":470,"phases":1500,"primaryCompletion":1501,"completion":349,"start":931,"enrollment":232,"conditions":1502,"interventions":1504},"NCT05986734","Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies",[],"2023-07-31",[1503],"Primary Immunodeficiency Diseases (PID)",[1483],{"intervention":1290,"totalTrials":91,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1515,"NA":1517},{"trials":1508,"activeCount":95},[],{"trials":1510,"activeCount":95},[],{"trials":1512,"activeCount":95},[],{"trials":1514,"activeCount":95},[],{"trials":1516,"activeCount":95},[],{"trials":1518,"activeCount":95},[1519],{"nctId":1281,"briefTitle":1282,"status":470,"phases":1520,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1521,"interventions":1522},[88],[22],[1290,1291,1292,1293,1294,1295,1228],{"intervention":1291,"totalTrials":91,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1531,"PHASE4":1533,"NA":1535},{"trials":1526,"activeCount":95},[],{"trials":1528,"activeCount":95},[],{"trials":1530,"activeCount":95},[],{"trials":1532,"activeCount":95},[],{"trials":1534,"activeCount":95},[],{"trials":1536,"activeCount":95},[1537],{"nctId":1281,"briefTitle":1282,"status":470,"phases":1538,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1539,"interventions":1540},[88],[22],[1290,1291,1292,1293,1294,1295,1228],{"intervention":1292,"totalTrials":91,"cells":1542},{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1547,"PHASE3":1549,"PHASE4":1551,"NA":1553},{"trials":1544,"activeCount":95},[],{"trials":1546,"activeCount":95},[],{"trials":1548,"activeCount":95},[],{"trials":1550,"activeCount":95},[],{"trials":1552,"activeCount":95},[],{"trials":1554,"activeCount":95},[1555],{"nctId":1281,"briefTitle":1282,"status":470,"phases":1556,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1557,"interventions":1558},[88],[22],[1290,1291,1292,1293,1294,1295,1228],{"intervention":1293,"totalTrials":91,"cells":1560},{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1562,"activeCount":95},[],{"trials":1564,"activeCount":95},[],{"trials":1566,"activeCount":95},[],{"trials":1568,"activeCount":95},[],{"trials":1570,"activeCount":95},[],{"trials":1572,"activeCount":95},[1573],{"nctId":1281,"briefTitle":1282,"status":470,"phases":1574,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1575,"interventions":1576},[88],[22],[1290,1291,1292,1293,1294,1295,1228],{"intervention":1294,"totalTrials":91,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1580,"activeCount":95},[],{"trials":1582,"activeCount":95},[],{"trials":1584,"activeCount":95},[],{"trials":1586,"activeCount":95},[],{"trials":1588,"activeCount":95},[],{"trials":1590,"activeCount":95},[1591],{"nctId":1281,"briefTitle":1282,"status":470,"phases":1592,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1593,"interventions":1594},[88],[22],[1290,1291,1292,1293,1294,1295,1228],{"intervention":1295,"totalTrials":91,"cells":1596},{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1598,"activeCount":95},[],{"trials":1600,"activeCount":95},[],{"trials":1602,"activeCount":95},[],{"trials":1604,"activeCount":95},[],{"trials":1606,"activeCount":95},[],{"trials":1608,"activeCount":95},[1609],{"nctId":1281,"briefTitle":1282,"status":470,"phases":1610,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1611,"interventions":1612},[88],[22],[1290,1291,1292,1293,1294,1295,1228]]